The eternal dilemma of antitoxin antibiotics for skin and soft tissue infection

Link to article at PubMed

Curr Opin Infect Dis. 2021 Apr 1;34(2):80-88. doi: 10.1097/QCO.0000000000000711.

ABSTRACT

PURPOSE OF REVIEW: In standard clinical practice, combined antibiotic treatment is used to treat severe skin and soft tissue infections (SSTIs), whereby one of the drugs is usually a protein synthesis inhibitor antibiotic. However, evidence for this practice is only based on data from 'in vitro' studies, animal models and case reports. There are no randomized controlled trials. In the light of several new drugs marketed for the treatment of these infections, there is a need to revise the state of the art.

RECENT FINDINGS: New reviews and systematic appraisals of the literature exist on the use of protein synthesis inhibitor antibiotics to treat severe SSTI. Several 'in vitro' studies have assessed the efficacy of some of the new drugs.

SUMMARY: Combination therapy, including an adjuvant protein synthesis inhibitor antibiotic for toxin suppression, should be used both in patients with severe SSTI and in those with moderate infection and risk factors for methicillin-resistant positive- or Panton-Valentine leukocidin positive-Staphylococcus aureus infection.

PMID:33560018 | DOI:10.1097/QCO.0000000000000711

Leave a Reply

Your email address will not be published.